Lotte Biologics Signs Antibody Biosimilar Manufacturing Agreement with Alvotech

Held at CPHI Milan 2026

Lotte Biologics will produce antibody biosimilars for the global biopharmaceutical company Alvotech. The company plans to accelerate the establishment of a 'dual-site' manufacturing system by initially commencing commercial production at its Syracuse, New York plant, and subsequently linking operations to the Songdo Bio Campus in Korea.

(From left) Shin Youyul, CEO of Lotte Biologics; James Park, CEO of Lotte Biologics; Lisa Graver, CEO of Albotech; and Robert Wesman, Chairman of Albotech, are taking a commemorative photo after signing a production order contract. Lotte Biologics

On October 7, Lotte Biologics announced that it had signed a production order contract for biopharmaceuticals with Alvotech. The signing ceremony took place at the 'CPHI Milan 2026' global pharmaceutical and biopharma exhibition held in Milan, Italy.

Under this agreement, Lotte Biologics will manufacture multiple antibody biosimilar drug substances for Alvotech at its Syracuse production facility in New York, United States. The products manufactured will be supplied to the global market.

The Syracuse facility is equipped with 40,000 liters of bioreactor capacity for biopharmaceutical manufacturing, as well as in-house process development and quality control capabilities. The plant has commercial-scale biopharmaceutical production experience and recently passed an unannounced U.S. Food and Drug Administration (FDA) inspection without any findings.

With this agreement, Alvotech will expand its manufacturing base in the United States and strengthen its global supply chain. By combining the additional manufacturing capabilities provided by Lotte Biologics with its own facilities and existing partnerships, Alvotech plans to respond to future product portfolio expansion and increasing global demand.

If the scale of cooperation increases going forward, Lotte Biologics intends to establish a dual-site production system linking the Syracuse facility and the Songdo Bio Campus in Incheon. The Songdo Bio Campus, which is currently under construction, will be connected with the U.S. facility to operate manufacturing sites according to clients’ global supply chains. Commercial supply will be carried out after technology transfer, manufacturing qualification assessments, and obtaining approvals from relevant regulatory agencies.

James Park, CEO of Lotte Biologics, stated, "We expect Alvotech's biosimilar development expertise and Lotte Biologics' global commercial manufacturing capabilities to create strong synergy. Depending on the expansion of our partnership, we will organically link the New York Syracuse and Songdo Bio Campus to support a dual-site manufacturing system optimized for global supply chains."

Lisa Graber, CEO of Alvotech, commented, "Our collaboration with Lotte Biologics allows us to secure additional manufacturing capacity in New York. As we prepare to expand our portfolio and launch new products in the future, this partnership will help supplement our existing manufacturing capabilities."

This content was produced with the assistance of AI translation services.